AbbVie (ABBV) has built a multibillion-dollar drug empire, steadily boosted its dividend, and developed a new generation of blockbuster medicines, making it a favorite among income-oriented investors.
The pharmaceutical giant is slated to report its third quarter results on Oct. 30, and expectations are running high. Investors are keen to see whether AbbVie's new medicines can deliver the earnings needed to sustain its remarkable 54-year dividend-growth streak, especially after Humira’s decline.